Search

Your search keyword '"Puoti, M"' showing total 1,477 results

Search Constraints

Start Over You searched for: Author "Puoti, M" Remove constraint Author: "Puoti, M"
1,477 results on '"Puoti, M"'

Search Results

1. Analysis of Patients’ Characteristics and Treatment Profile of People Who Use Drugs (PWUDs) with and without a Co-Diagnosis of Viral Hepatitis C: A Real-World Retrospective Italian Analysis

2. Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy

3. Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort

4. Multiple concomitanti infezioni opportunistiche e linfomi aggressivi in una persona con HIV/AIDS che non assumeva la terapia ant

5. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

6. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort

7. Surge of Mpox cases in Lombardy region, Italy, October 2023 - January 2024

8. Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management

9. Dynamics of viral DNA shedding and culture viral DNA positivity in different clinical samples collected during the 2022 mpox outbreak in Lombardy, Italy

10. Multi-Criteria Decision Analysis to prioritize hospital admission of patients affected by COVID-19 in low-resource settings with hospital-bed shortage

11. Quantitative SARS-CoV-2 subgenomic RNA as a surrogate marker for viral infectivity: Comparison between culture isolation and direct sgRNA quantification

13. Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study

14. A case of chronic bacterial prostatitis due to Mycoplasma genitalium

15. Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort

16. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience

17. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

18. A territory-wide opportunistic, hospital-based HCV screening in the general population from northern Italy: The 1969–1989 birth-cohort

19. Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi

20. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

21. Similar survival but higher and delayed hepatocellular carcinoma recurrence in HIV-positive compared to negative cirrhotics undergoing liver transplantation

22. Analysis of Patients’ Characteristics and Treatment Profile of People Who Use Drugs (PWUDs) with and without a Co-Diagnosis of Viral Hepatitis C: A Real-World Retrospective Italian Analysis

23. Corrigendum to: “Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study)” Clinical Microbiology and Infection 26 (2020) 1545–1553 (Clinical Microbiology and Infection (2020) 26(11) (1545–1553), (S1198743X20304791), (10.1016/j.cmi.2020.08.003))

24. Hepatocellular Carcinoma in HIV-Infected Patients: Clinical Presentation and Outcomes

26. The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic-Clinical Management of HIV-1 Infected Persons

27. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper

28. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

29. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection

30. Antibody Response to COVID-19 Booster Vaccination in Healthcare Workers

31. A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort

32. Discordant liver fibrosis predictors in virologically suppressed people living with hiv without hepatitis virus infection

33. Trends in all-cause mortality of hospitalized patients due to SARS-CoV-2 infection from a monocentric cohort in Milan (Lombardy, Italy)

34. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study

36. Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di)

37. Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study

39. The role of intravenous immunoglobulin in the treatment of community-acquired West Nile virus encephalitis after liver transplantation

40. Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy

41. Impact of treatment with direct-acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co-infected individuals

42. Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade

44. HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection

45. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

47. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

48. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement

49. Vaccinations in patients with multiple sclerosis: A Delphi consensus statement

50. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study

Catalog

Books, media, physical & digital resources